CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer

The chemokine CXCL9 (C-X-C motif chemokine ligand 9) has been reported to be required for antitumour immune responses following immune checkpoint blockade. In this study, we sought to investigate the potential value of CXCL9 according to immune responses in patients with breast cancer (BC). A variet...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yuan-ke, Deng, Ze-kun-, Chen, Mu-tong, Qiu, Si-qi, Xiao, Ying-sheng, Qi, Yu-zhu, Xie, Qin, Wang, Zheng-hao, Jia, Shi-cheng, Zeng, De, Lin, Hao-yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435794/
https://www.ncbi.nlm.nih.gov/pubmed/34527583
http://dx.doi.org/10.3389/fonc.2021.710286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435794/
https://www.ncbi.nlm.nih.gov/pubmed/34527583
http://dx.doi.org/10.3389/fonc.2021.710286

Ejemplares similares